Sanofi-Regeneron’s Dupixent drug has received FDA approval for ‘smoker’s lungs’
The U.S. Food and Drug Administration approved Sanofi and Regeneron companies said Friday that the blocker drug Dupixent is intended for patients with chronic lung disease, commonly known as ‘smoker’s lung.’
BELIEBTE BEITRÄGE
IEA warns ‘electricity era’ will come after fossil fuels peak
Oktober 17, 2024
Easter Island fights global plastic waste vortex
Oktober 17, 2024
Egypt opens more galleries at its antiquities museum
Oktober 17, 2024
LIVEÜBERTRAGUNG